Ikinciogullari Aykut, Hazir Burak, Aggunlu Erdem, Colak Mustafa, Ensari Serdar, Dere Haci Huseyin
Department of Otorhinolaryngology Head and Neck Surgery, Ankara Bilkent City Hospital, Ankara, Turkey.
Med Sci Monit. 2025 Aug 17;31:e947334. doi: 10.12659/MSM.947334.
BACKGROUND Salivary gland neoplasms present a diagnostic challenge due to their heterogeneous nature and varying histological subtypes. Recent studies have highlighted the potential role of inflammatory biomarkers, such as neutrophil to lymphocyte ratio (NLR) and systemic immune inflammation index (SII), in enhancing diagnostic accuracy for distinguishing between benign and malignant parotid gland tumors. This study aimed to evaluate the use of inflammatory biomarkers - NLR, platelet-to-lymphocyte ratio (PLR), SII, and systemic inflammation response index (SIRI) - in the differential diagnosis of parotid gland tumors. MATERIAL AND METHODS Patients who underwent parotidectomy in a single center between 2019 and 2023 were included. Inflammatory biomarkers (NLR, PLR, SII, SIRI) were calculated and compared according to histopathological features (benign vs malignant) and subgroups (benign: pleomorphic adenoma, Warthin, and others; and malignant: high grade, low grade, and lymphoma. RESULTS A total of 206 patients were included in the study (benign: 177, malignant: 29). No significant difference was detected in NLR, PLR, SII and SIRI values between benign and malignant tumor groups. While all inflammatory markers were found to be elevated, only PLR exhibited a statistically significant difference among high-grade, low-grade, and benign tumor groups (P=0.05). Patients with Warthin tumor revealed significantly lower PLR and higher SIRI values than those with pleomorphic adenoma (P=0.02 and P<0.001, respectively). CONCLUSIONS Evaluation of inflammatory biomarkers seems to play a promising role in diagnosing parotid tumors, especially Warthin tumor and high-grade malignancies. Due to their accessibility and cost-effectiveness, further studies are warranted to determine their accuracy and optimal use in clinical practice.
背景 唾液腺肿瘤因其异质性和不同的组织学亚型而带来诊断挑战。最近的研究强调了炎症生物标志物，如中性粒细胞与淋巴细胞比值（NLR）和全身免疫炎症指数（SII），在提高鉴别腮腺良性和恶性肿瘤诊断准确性方面的潜在作用。本研究旨在评估炎症生物标志物——NLR、血小板与淋巴细胞比值（PLR）、SII和全身炎症反应指数（SIRI）——在腮腺肿瘤鉴别诊断中的应用。材料与方法 纳入2019年至2023年在单一中心接受腮腺切除术的患者。根据组织病理学特征（良性与恶性）和亚组（良性：多形性腺瘤、沃辛瘤和其他；恶性：高级别、低级别和淋巴瘤）计算并比较炎症生物标志物（NLR、PLR、SII、SIRI）。结果 本研究共纳入206例患者（良性：177例，恶性：29例）。良性和恶性肿瘤组之间的NLR、PLR、SII和SIRI值未检测到显著差异。虽然发现所有炎症标志物均升高，但只有PLR在高级别、低级别和良性肿瘤组之间表现出统计学显著差异（P = 0.05）。沃辛瘤患者的PLR值明显低于多形性腺瘤患者，SIRI值明显高于多形性腺瘤患者（分别为P = 0.02和P < 0.001）。结论 炎症生物标志物的评估似乎在腮腺肿瘤的诊断中发挥着有前景的作用，尤其是沃辛瘤和高级别恶性肿瘤。由于其可及性和成本效益，有必要进一步研究以确定它们在临床实践中的准确性和最佳用途。
